Antidepressant Controlled Trial for Negative Symptoms in Schizophrenia

PHASE4CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

December 31, 2014

Study Completion Date

January 31, 2015

Conditions
Schizophrenia
Interventions
DRUG

Citalopram

Treatment with citalopram will be initiated at 20mg/day for the first 4 weeks (or one placebo capsule), followed by the option to increase the dose to 40mg per day (or two placebo capsules) for the remainder of the study period.

DRUG

Placebo

Treatment with citalopram will be initiated at 20mg/day for the first 4 weeks (or one placebo capsule), followed by the option to increase the dose to 40mg per day (or two placebo capsules) for the remainder of the study period.

Trial Locations (14)

Unknown

Avon and Wiltshire mental health partnership, Bristol

Derbyshire healthcare NHS foundation trust, Derby

Lincolnshire partnership NHS foundation trust, Lincoln

Camden and Islington NHS foundation trust, London

Central and North West London NHS foundation trust, London

Oxleas NHS foundation trust, London

South London and the Maudsley, London

Manchester health and social care trust, Manchester

Northumberland, Tyne and Wear NHS foundation trust, Newcastle

Oxfordshire and Buckinghamshire NHS foundation trust, Oxford

Sheffield social care foundation trust, Sheffield

South Staffordshire and Shropshire NHS foundation trust, Stafford

W6 8RP

West london Mental Health Trust, London

SO14 0YG

Southern Health, Southampton

All Listed Sponsors
collaborator

University of Manchester

OTHER

collaborator

University of Southampton

OTHER

collaborator

King's College London

OTHER

collaborator

University of Oxford

OTHER

collaborator

University College, London

OTHER

collaborator

University of Bristol

OTHER

lead

Imperial College London

OTHER

NCT01032083 - Antidepressant Controlled Trial for Negative Symptoms in Schizophrenia | Biotech Hunter | Biotech Hunter